Aktuellt
SENASTE
Redeye comments on Immunicum presenting ADVANCE II data at ASH 2021. We judge that the presented data confirm the promising results reported in a previously published abstract. Thus, ADVANCE II top-line data align with our expectations, and we reiterate our view that DCP-001 has a bright future in AML, warranting further clinical studies. Among Immunicum’s pipeline projects, we currently assign the highest likelihood of approval to DCP-001 in AML.
LÄS MER
